



## INTERNAL MEMORANDUM

| SN | CTA # | Title  | Principal Investigator   | Applicant   |
|----|-------|--|--------------------------|---|
| 1. | 0001  | Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-center, parallel-group, two arm randomized placebo controlled superiority trial   | Dr. Robert Opika Opoka   | Department of Pediatrics and Child Health, Makerere University College of Health Sciences |
| 2. | 0002  | Doxycycline for the treatment of nodding syndrome: A phase II, randomised placebo controlled trial   | Dr. Richard Idro         | Department of Pediatrics and Child Health, Makerere University College of Health Sciences |
| 3. | 0003  | Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability, and Anti-Retroviral Activity of GSK 1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents  | Dr. Linda Barlow Mosha   | MU-JHU Care Ltd.  |
| 4. | 0004  | Prevention of Malaria in HIV-uninfected Pregnant Women and Infants (PROMISE Birth Cohort 3)  | Prof. Moses Kamya        | MU-UCSF   |
| 5. | 0005  | A Phase 3, Randomized , Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS -9883/ Emtricitabine/Tenofovir Alafenamide (GS - 9883/F/TAF) from Elvitegravir /Cobicistat /Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF), or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumerate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women | Dr. Cissy Kityo Mutuluza | Joint Clinical Research Centre  |
| 6. | 0006  | A randomized trial of dolutegravir (DTG)-based antiretroviral therapy vs standard of care (SOC) in children with HIV infection starting first line or switching to second line ART.  | Dr. Cissy Kityo Mutuluza | Joint Clinical Research Centre  |



**INTERNAL MEMORANDUM**

|     |      |   |                         |  |
|-----|------|---|-------------------------|--|
| 7.  | 0007 | Pharmacokinetics of efirvirenz 400 mg once daily during pregnancy in HIV -1 infected women.   | Dr. Mohammed Lamorde    | Infectious Disease Institute                           |
| 8.  | 0008 | <b>IN</b> VeStIgation of rheumatIc AF Treatment <b>U</b> Using vitamin K antagonists, rivaroxaban or aspirin <b>S</b> tudies. (INVICTUS)  | Dr. Emmy Okello         | Uganda Heart Institute                                 |
| 9.  | 0009 | A Multi-center, Phase 3B Open-label Follow-up trial to assess the continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women.   | Dr. Brenda Gati Mirembe | MUJHU care Ltd.  |
| 10. | 0010 | A Multi-country, prospective, clinical safety study of subjects exposed to the candidate Ebola vaccines Ad26.ZEBOV and/or MVA –BN-Filo  | Prof. Pontiano Kaleebu  | MRC/UVRI   |
| 11. | 0011 | A Pharmacokinetic Evaluation of Increased Dose Levonogestrel Implant and Efavirenz-Based Antiretroviral Therapy In HIV-Infected Women   | Dr. Mohammed Lamorde    | Infectious Diseases Institute                          |
| 12. | 0012 | A multicenter, open label , randomized , multiple dose , two period crossover, bioequivalence study of Liposomal Amphotericin B injection (Cipla Ltd. , India) and Ambisome® Liposome for injection (Gilead life sciences, USA ) in adult patients with fungal infections | Dr. Henry Mugerwa       | Joint Clinical Research Centre                         |
| 13. | 0013 | A Follow-Up Open Label Trial to Assess The Continued Safety of and Adherence to the Dapivirine (25mg) Vaginal Ring-004 in Healthy HIV-Negative Women (Phase IIIb)   | Dr. Sylvia Kusemererwa  | MRC/UVRI   |
| 14. | 0014 | Strategy for Maintenance of HIV Suppression with Elvitegravir + Darunavir +Ritonavir in Children (SMILE PROTOCOL)   | Dr. Victor Musime       | Joint Clinical Research Centre                         |
| 15. | 0015 | Defining the Molecular profile of Breast Cancer in Uganda and its Clinical Implications   | Dr. Jackson Orem        | Uganda Cancer Institute                                |
| 16. | 0016 | Optimizing Hydroxyurea Therapy in Children with Sickle Cell Anemia in Malaria Endemic Areas : The NOHARM Maximum Tolerated Dose (MTD) Extension Study   | Dr. Robert Opika Opoka  | Global Health Uganda / PEDIATRIC DEPT. Mulago Hospital |



**INTERNAL MEMORANDUM**

|     |      |   |                         |  |
|-----|------|---|-------------------------|--|
| 17. | 0017 | The effect of modified F-75 on diarrhea in the treatment of children with severe acute malnutrition.  | Dr. Elizabeth Kiboneka  | Mwana Mugimu Nutrition Unit, Mulago Hospital |
| 18. | 0018 | A Phase 2/3 , Open Label Study of the Pharmacokinetics , Safety, and Antiviral Activity of the GS-9883/ Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) in HIV-1 infected Virologically Suppressed Adolescents and Children | Dr. Eva Natukunda       | Joint Clinical Research Centre               |
| 19. | 0021 | An open label phase I clinical trial to evaluate the effect of late boost on HIV-uninfected vaccines from EV06 trial  | Prof. Pontiano Kaleebu  | MRC/UVRI                                     |
| 20. | 0022 | Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans (CREOLE)   | Dr. Mondo Charles Kiiza | St. Francis Hospital Nsambya                 |
| 21. | 0023 | Phase 1 Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-I Infection   | Dr. Jesca Nakibuuka     | MU-JHU care Ltd.                             |
| 22. | 0024 | Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial  | Prof. Peter Mugenyi     | Joint Clinical Research Centre               |
| 23. | 0025 | <i>AN INTERNATIONAL MULTICENTRE CONTROLLED CLINICAL TRIAL TO EVALUATE 1200mg AND 1800mg RIFAMPICIN DAILY IN THE REDUCTION OF TREATMENT DURATION FOR PULMONARY TUBERCULOSIS FROM 6 MONTHS TO 4 MONTHS (RIFASHORT)</i>            | Dr. Daniel Atwine       | Epicentre - Mbarara Research Base            |
| 24. | 0026 | Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis among Women at High Risk for HIV infection in Kampala, Uganda                                    | Prof. Janet Seeley      | MRC/UVRI                                     |
| 25. | 0027 | <i>The evaluation of a standard treatment regimen of anti-tuberculosis drugs for patients with MDR-TB (STREAM)</i>  | Dr. Bruce Kirenga       | Makerere University – Lung Institute         |
| 26. | 0028 | <i>Assessing the tolerability and safety of single low dose Primaquine in African Children with Acute Uncomplicated Falciparum Malaria and Glucose-6-Phosphate Dehydrogenase Deficiency</i>                                     | Dr. Peter Olupot-Olupot | Mbale Clinical Research Institute            |



NATIONAL DRUG AUTHORITY  
**INTERNAL MEMORANDUM**

Doc. No.: QMS/FOM /143  
Revision No.:1  
Effective Date: 4 Mar 2016

Page 4 of 4

---

|     |      |   |                         |                                   |
|-----|------|---|-------------------------|-----------------------------------|
| 27. | 0029 | <i>First line Antimicrobials in Children with complicated Severe Acute Malnutrition (FLACSAM)</i> | Dr. Peter Olupot-Olupot | Mbale Clinical Research Institute |
|-----|------|---|-------------------------|-----------------------------------|

**Abbreviations**

1. MRC/UVRI Medical Research Council /Uganda Virus Research Institute
2. MU-UCSF Makerere University – University of California, San Francisco
3. MU-JHU Makerere University – John Hopkins University